We have already briefly discussed both the OPG-RANKL-RANK system and the Wnt-β-catenin signaling pathway, and that these monoclonal antibodies (anti-RANKL and antisclerostin, respectively) are not contraindicated in CKD or dialysis patients with OP. This evidence concerns the gene TNFRSF11B and chronic kidney disease.